4.4 Review

Kappa opioids and the modulation of pain

Journal

PSYCHOPHARMACOLOGY
Volume 210, Issue 2, Pages 109-119

Publisher

SPRINGER
DOI: 10.1007/s00213-010-1819-6

Keywords

Dynorphin; Kappa opioid; Hallucinogen; Opioid; Salvinorin A; Salvia divinorum; Pain

Ask authors/readers for more resources

Pain is a complex sensory experience, involving cognitive factors, environment (setting, society, and culture), experience, and gender and is modulated significantly by the central nervous system (CNS). The mechanisms by which opioid analgesics work are understood, but this class of drugs is not ideal as either an analgesic or anti-hyperalgesic. Accordingly, considerable effort continues to be directed at improved understanding of nociceptor function and development of selective analgesics that do not have the unwanted effects associated with opioid analgesics. The purpose of this paper is to provide a review of the role of KOP receptors in the modulation of pain and highlight several chemotypes currently being explored as peripherally restricted KOP ligands. A growing body of literature has shown that KOP receptors are implicated in a variety of behavioral pain models. Several different classes of peripherally restricted peptidic and nonpeptidic KOP agonists have been identified and show utility in treating painful conditions. The pharmacological profile of KOP agonists in visceral pain models suggest that peripherally restricted KOP agonists are potentially useful for a variety of peripheral pain states. Further, clinical investigation of peripherally restricted KOP agonists will help to clarify the painful conditions where KOP agonists will be most effective.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Immunology

Nalfurafine reduces neuroinflammation and drives remyelination in models of CNS demyelinating disease

Lisa Denny, Afnan Al Abadey, Katharina Robichon, Nikki Templeton, Thomas E. Prisinzano, Bronwyn M. Kivell, Anne C. La Flamme

Summary: Nalfurafine shows potential in promoting recovery and remyelination in multiple sclerosis (MS), mediating recovery in EAE in a KOR-dependent fashion, reducing CNS infiltration, especially CD4(+) and CD8(+) T cells, and promoting a more immunoregulatory environment, while also promoting remyelination in the absence of peripheral immune cell invasion in the cuprizone demyelination model.

CLINICAL & TRANSLATIONAL IMMUNOLOGY (2021)

Article Neurosciences

The mixed kappa and delta opioid receptor agonist, MP1104, attenuates chemotherapy-induced neuropathic pain

Diana Vivian Atigari, Kelly Frances Paton, Rajendra Uprety, Andras Varadi, Amy Frances Alder, Brittany Scouller, John H. Miller, Susruta Majumdar, Bronwyn Maree Kivell

Summary: Addressing the urgent need for effective treatments for chronic pain, research suggests that mixed opioid receptor agonists targeting KOP and DOP could provide non-addictive pain medications with a wider therapeutic index. A novel compound, MP1104, demonstrates potent antinociceptive effects mediated via KOP and DOP without inducing rewarding or aversive effects.

NEUROPHARMACOLOGY (2021)

Article Clinical Neurology

Discriminative-Stimulus Effects of Synthetic Cathinones in Squirrel Monkeys

Alison G. P. Wakeford, Alexander M. Sherwood, Thomas E. Prisinzano, Jack Bergman, Stephen J. Kohut, Carol A. Paronis

Summary: The study systematically evaluated the discriminative stimulus effects of 5 abused synthetic cathinones in nonhuman primates, suggesting that their differences in monoaminergic actions may mediate their subjective effects in humans.

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2021)

Article Clinical Neurology

Profile of a short-acting κ-antagonist, LY2795050, on self-grooming behaviors, forced swim test and locomotor activity: sex comparison in mice

Eduardo R. Butelman, Caroline Baynard, Bryan D. McElroy, Thomas E. Prisinzano, Mary Jeanne Kreek

Summary: The study revealed sex differences in the responses of male and female mice to κ-agonists and short-acting κ-antagonists in the splash test of self-grooming. Males showed reduced immobility in the FST at a certain dose, while females did not; LY2795050 was able to block and reverse the locomotor depressant effects of U50,488 in both males and females.

JOURNAL OF PSYCHOPHARMACOLOGY (2021)

Article Pharmacology & Pharmacy

Structure-activity studies of PTPRD phosphatase inhibitors identify a 7-cyclopentymethoxy illudalic acid analog candidate for development

Ian M. Henderson, Fanxun Zeng, Nazmul H. Bhuiyan, Dan Luo, Maria Martinez, Jane Smoake, Fangchao Bi, Chamani Perera, David Johnson, Thomas E. Prisinzano, Wei Wang, George R. Uhl

Summary: This study reports a novel candidate PTPRD phosphatase inhibitor with high potency and selectivity. The compound showed good oral bioavailability and tolerance in in vivo studies, suggesting its potential role in reducing reward from addictive substances.

BIOCHEMICAL PHARMACOLOGY (2022)

Review Behavioral Sciences

The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders

Jeffrey M. Witkin, Arnold Lippa, Jodi L. Smith, Xiaoming Jin, Xingjie Ping, Andrew Biggerstaff, Bronwyn M. Kivell, Daniel E. Knutson, Dishary Sharmin, Kamal P. Pandey, Md Yeunus Mian, James M. Cook, Rok Cerne

Summary: This article discusses the history and recent developments of GABAkines, introducing various new compounds and steroids for the treatment of neurological and psychiatric conditions.

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2022)

Review Pharmacology & Pharmacy

The Kappa Opioid Receptor: A Promising Therapeutic Target for Multiple Pathologies

Martin L. Dalefield, Brittany Scouller, Rabia Bibi, Bronwyn M. Kivell

Summary: Kappa-opioid receptors have wide-ranging effects on various physiological processes and hold therapeutic potential for pain, pruritis, and other diseases. However, adverse effects limit their clinical use, highlighting the need for further development.

FRONTIERS IN PHARMACOLOGY (2022)

Article Biochemistry & Molecular Biology

Synthesis and Pharmacological Evaluation of Enantiopure N-Substituted Ortho-c Oxide-Bridged 5-Phenylmorphans

Fuying Li, Theresa A. Kopajtic, Jonathan L. Katz, Dan Luo, Thomas E. Prisinzano, Gregory H. Imler, Jeffrey R. Deschamps, Arthur E. Jacobson, Kenner C. Rice

Summary: This study focuses on the design and synthesis of enantiopure stereoisomers of N-2-phenylcyclopropylmethyl-substituted ortho-c oxide-bridged phenylmorphans as potential opioid receptor ligands. The compounds were synthesized and evaluated for their affinity and functional activity.

MOLECULES (2022)

Article Neurosciences

Sex Differences in the Behavioural Aspects of the Cuprizone-Induced Demyelination Model in Mice

Kelly F. Paton, Sheein Hong, Andrew Biggerstaff, Bronwyn M. Kivell

Summary: This study investigates the behavioral deficits associated with cuprizone-induced demyelination in male and female mice. The results show sex differences in motor coordination and anxiety-like behaviors, providing a better understanding of the behavioral aspects of cuprizone-induced demyelination.

BRAIN SCIENCES (2022)

Article Biochemistry & Molecular Biology

Discovery of a Potent Highly Biased MOR Partial Agonist among Diastereomeric C9-Hydroxyalkyl-5-phenylmorphans

Joshua A. Lutz, Agnieszka Sulima, Eugene S. Gutman, Eric W. Bow, Dan Luo, Sophia Kaska, Thomas E. Prisinzano, Carol A. Paronis, Jack Bergman, Gregory H. Imler, Andrew T. Kerr, Arthur E. Jacobson, Kenner C. Rice

Summary: All possible diastereomeric C9-hydroxymethyl-, hydroxyethyl-, and hydroxypropyl-substituted 5-phenylmorphans were synthesized to explore the three-dimensional space around the C9 substituent in search for potent MOR partial agonists. Many of these compounds exhibited nanomolar or subnanomolar potency and were fully efficacious. One compound in particular, 21, showed good potency and efficacy as a MOR partial agonist, as well as selectively activating G-protein signaling pathway. Overall, the study highlights the importance of structural modification in developing new opioids with improved analgesic properties.

MOLECULES (2023)

Article Biochemistry & Molecular Biology

The Kappa Opioid Receptor Agonist 16-Bromo Salvinorin A Has Anti-Cocaine Effects without Significant Effects on Locomotion, Food Reward, Learning and Memory, or Anxiety and Depressive-like Behaviors

Ross van de Wetering, Amy Ewald, Susan Welsh, Lindsay Kornberger, Samuel E. Williamson, Bryan D. McElroy, Eduardo R. Butelman, Thomas E. Prisinzano, Bronwyn M. Kivell

Summary: This preclinical study evaluated the G-protein-biased analogue of SalA, 16-BrSalA, for its anticocaine effects and side effects, and found that it has improved pharmacokinetic profiles and fewer side effects.

MOLECULES (2023)

Article Biochemistry & Molecular Biology

A MOR Antagonist with High Potency and Antagonist Efficacy among Diastereomeric C9-Alkyl-Substituted N-Phenethyl-5-(3-hydroxy)phenylmorphans

Dana R. Chambers, Agnieszka Sulima, Dan Luo, Thomas E. Prisinzano, Arthur E. Jacobson, Kenner C. Rice

Summary: The 5-(3-hydroxy)phenylmorphan structural class of compounds have an equatorially oriented aromatic ring and retain antinociceptive activity. The synthesized C9-alkyl diastereomers have been found to interact with opioid receptors and exhibit varying efficacy, including potent MOR agonists and a selective MOR antagonist that is more potent than naltrexone and antagonizes the EC90 of fentanyl to a greater extent.

MOLECULES (2023)

Article Biochemistry & Molecular Biology

A Journey through Diastereomeric Space: The Design, Synthesis, In Vitro and In Vivo Pharmacological Activity, and Molecular Modeling of Novel Potent Diastereomeric MOR Agonists and Antagonists

Dana R. Chambers, Agnieszka Sulima, Dan Luo, Thomas E. Prisinzano, Alexander Goldberg, Bing Xie, Lei Shi, Carol A. Paronis, Jack Bergman, Nima Nassehi, Dana E. Selley, Gregory H. Imler, Arthur E. Jacobson, Kenner C. Rice

Summary: Four sets of diastereomeric C9-alkenyl 5-phenylmorphans with different lengths of the C9-alkenyl chain were designed to examine their effects on opioid receptors. The study found similarities and differences in their functional activities and pharmacological properties, and identified potential structures that contribute to these differences through molecular modeling.

MOLECULES (2022)

No Data Available